Research

Feb. 27, 2017
Exonics Therapeutics
Exonics Therapeutics Launches with Funding from CureDuchenne Ventures to Advance CRISPR/Cas9 Therapy for Duchenne Muscular Dystrophy


Feb. 9, 2017
Marathon Pharmaceuticals
EMFLAZA™ (deflazacort) has just been FDA-approved


Feb. 9, 2017
FDA News Release
FDA approves drug to treat Duchenne muscular dystrophy


Jan. 31, 2017
Catabasis Pharmaceuticals
Catabasis Pharmaceuticals Announces Top-Line Results for Part B of the MoveDMD® Trial for Edasalonexent (CAT-1004) in Duchenne Muscular Dystrophy


Nov. 11, 2016
PTC Therapeutics
CHMP Recommends Renewal of Translarna’s™ Marketing Authorization for Nonsense Mutation Duchenne Muscular Dystrophy Based on Continued Positive Benefit-Risk Assessment


Nov. 10, 2016
Capricor Therapeutics
Capricor Therapeutics Announces Plans to Expand Clinical Development Program in Duchenne Muscular Dystrophy to Evaluate Peripheral and Respiratory Muscle Function


Oct. 31, 2016
The Collaborative Trajectory Analysis Project (cTAP)
cTAP ANNOUNCES TWO RESEARCH PUBLICATIONS CATEGORIZING AND PREDICTING DISEASE
PROGRESSION IN DUCHENNE MUSCULAR DYSTROPHY


Oct. 6, 2016
PTC Therapeutic
PTC Therapeutics Announces New Analyses that Support the Potential Benefit of Ataluren in Preserving Lung Function in Non-Ambulatory Nonsense Mutation Duchenne Muscular Dystrophy Patients


Oct 4, 2016
Catabasis Pharmaceuticals
Catabasis Pharmaceuticals Completes Target Enrollment for Part B of the MoveDMD® Trial, a Phase 2 Trial of Edasalonexent (CAT-1004) for the Potential Treatment of Duchenne Muscular Dystrophy


Hike for Hope is operating under the HIKE FOR HOPE FOUNDATION INC
936 W Francis St., Aspen, CO. 81611
Tel: 970-925-6137,
Tax-exempt 501 (c)(3)
charitable organization.
Tax ID 20-3596738